课题基金 / 基金详情

Genes & Health Longitudinal Population Study

Genes & Health Longitudinal Population Study
基因
批准号:
MR/X009920/1
负责人:
Sarah Finer
金额:
$259.05万
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2023
资助国家:
英国
项目状态:
未结题
起止时间:
2023 至 --

项目摘要

项目成果

Sarah Finer的其他基金

相似基金

相关文献

中文摘要
翻译
基因与健康是一项大型研究,涉及英国、孟加拉国和巴基斯坦人的健康研究。与白色欧洲人相比,来自这些背景的人健康状况不佳的比例更高(例如,2型糖尿病和心血管疾病的发病率分别为4倍和2倍)。英国南亚人所面临的健康不平等,由于他们在健康和基因组研究中的代表性不足而进一步加剧。例如,全球全基因组关联研究(最常见的遗传研究类型之一)中只有约2%的参与者是南亚人,尽管他们占世界人口的25%。Genes & Health成功地纠正了这种不平衡,并证明了其对全球研究舞台的宝贵贡献。自2015年成立以来,Genes & Health通过与其代表的社区进行广泛而持久的接触,已成功招募了50,455名志愿者。基因与健康是一种科学资源,可供全球研究界使用,从而确保从这些志愿者的贡献中获得最大的健康益处。通过基因与健康已经支持的研究,它已经产生了几个重大影响,包括:i.发现完整基因敲除如何促进健康和疾病。支持开发一种新药(Lumasiran),用于治疗一种导致儿童严重健康不良的罕见遗传病iii。对一个财团的重大贡献,该财团揭示了我们的基因如何使我们更容易患上COVID-19 iv或因COVID-19 iv而不适。使用遗传数据改善对2型糖尿病风险的预测。揭示一种涉及儿童生长和青春期的新生物途径尽管取得了这些早期的成功,但基因与健康现在正处于一个关键阶段,其可持续性和增长潜力不确定。在MRC纵向人口研究计划的资助下,基因与健康将能够维持自己作为英国南亚人这一代表性不足的人口的健康和疾病的长期研究,与其他有价值的研究队列研究一起工作,以获得最大的利益。这笔资金还将使基因与健康发展,更好地解决尚未得到满足的健康需求领域,包括心理健康和怀孕健康。我们的建议集中在以下几个方面:1。通过支持其核心研究团队,支持Genes & Health的整体可持续性,超越其当前基础设施资金的期限,并生成丰富的纵向数据。2.提供基因与健康“回忆”研究的增长,其中现有的志愿者被邀请参加额外的研究,并在显着的附加值所在3。扩大心理健康和怀孕方面的数据收集,以解决未得到满足的健康需求领域4。我们将继续扩大基因与健康数据资源,以确保其与其他队列研究保持一致,以确保分析结果大于各部分的总和。为此,我们寻求额外的资金,以支持一些额外的高级学术专家的投入,并扩大个人团队,以实现我们的目标。
英文摘要
Genes & Health is a large study involving British Bangladeshi and Pakistani people in health research. People from these backgrounds experience higher rates of ill health compared to White Europeans (e.g. type 2 diabetes and cardiovascular disease are four times and twice as common, respectively). The health inequalities faced by British south Asians are further exacerbated by their underrepresentation in health and genomic research. For example, only ~2% of participants in global genome-wide association studies (one of the commonest types of genetic study) are south Asian despite making up ~25% of the world's population. Genes & Health is succeeding in redressing some of this imbalance and is proving a valuable contributor to the global research stage.Since it started in 2015, Genes & Health has managed to recruit 50,455 volunteers, through extensive and lasting engagement with the communities it represents. Genes & Health exists as a scientific resource available for a global research community to use, thereby ensure that the greatest benefits to health are achieved from the contributions of these volunteers. Through the research that Genes & Health has already supported, it has already had several major impacts, including:i. Discovering how complete gene knockouts contribute to health and diseaseii. Supporting development of a new drug (Lumasiran) for a rare genetic disease causing severe ill-health in childreniii. A significant contribution to a consortium uncovering how our genes make us more susceptible to developing, or getting unwell from, COVID-19iv. Improving the prediction of who is at risk of developing type 2 diabetes using genetic datav. Uncovering a new biological pathway involved in childhood growth and pubertyDespite these early successes, Genes & Health is now at a critical phase, with its sustainability and potential for growth uncertain. With funding from the MRC Longitudinal Population Study scheme, Genes & Health will be able to sustain itself as a long-term study of health and disease in this underrepresented population of British south Asians, working together with other valuable research cohort studies for maximal benefit. This funding will also allow Genes & Health to grow and better address areas of health need which remain unmet, including mental health and pregnancy health. Our proposal focuses on the following areas:1. Supporting the overall sustainability of Genes & Health through support of its core research team, beyond the duration of its current infrastructure funding, and to generate rich longitudinal data.2. Delivering growth of Genes & Health 'recall' studies, where its existing volunteers are invited to participate in additional research, and where significant added value lies3. Expanding data collection in mental health and pregnancy, to address areas of unmet health need4. Growing the Genes & Health data resource to ensure it can be aligned to other cohort research studies to ensure analyses that are greater than the sum of their parts.To do this, we seek additional funding, which will support the input of some additional senior academic experts, and an expanded team of individuals to deliver our ambition.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
CYP2C19 loss-of-function alleles are not associated with higher prevalence of gastrointestinal bleeds in those who have been prescribed antidepressants: Analysis in a British-South Asian cohort
CYP2C19 功能丧失等位基因与服用抗抑郁药的患者胃肠道出血患病率较高无关:英国-南亚队列分析
DOI: 10.1111/bcp.15762
发表时间: 2023
期刊: British Journal of Clinical Pharmacology
影响因子: 3.4
作者: [Magavern E]
通讯作者: Magavern E
Multimorbidity clusters, trajectories and genetic risk, in British south Asians
  • 批准号:
    MR/S027297/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $64.43万
  • 财政年份:
    2020
  • 负责人:
    Sarah Finer
  • 依托单位:
Does abnormal one-carbon metabolism or hyperglycaemia in utero cause epigenetic change and fetal programming of cardiome
  • 批准号:
    G0800441/1
  • 项目类别:
    Fellowship
  • 资助金额:
    $28.96万
  • 财政年份:
    2008
  • 负责人:
    Sarah Finer
  • 依托单位:
国内基金
海外基金
基于One Health理念的狂犬病传播风险多源驱动机制与协同防控策略研究
重大传染病防治关键技术研究-重大传染病防治关键技术研究-基于One Health的SFTS防治技术体系构建与应用
  • 批准号:
    2025C02186
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    孙继民
  • 依托单位:
人兽共患病One Health防控决策路径研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    5.0万元
  • 批准年份:
    2024
  • 负责人:
    张晓溪
  • 依托单位:
基于 One Health 策略的 mcr 阳性多重耐药 ST34 型沙门菌的流行传播机制及溯源研究
  • 批准号:
    Y24H190002
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    罗琦霞
  • 依托单位: